ストックスクリーナーアプリを入手
57.85
0.64%
0.37
アフターアワーズ：
57.85
前日終値:
$57.48
開ける：
$57.79
24時間の取引高:
1.27M
Relative Volume:
0.51
時価総額：
$5.38B
収益：
$536.20M
当期純損益:
$-45.64M
株価収益率:
-108.17
EPS:
-0.5348
ネットキャッシュフロー:
$-28.94M
1週間 パフォーマンス:
+1.83%
1か月 パフォーマンス:
+26.28%
6か月 パフォーマンス:
+59.45%
1年 パフォーマンス:
+296.10%
1日の値動き範囲:
$56.45
$58.79
1週間の範囲:
$54.87
$58.79
52週間の値動き範囲:
$14.69
$60.10
Travere Therapeutics Inc Stock (TVTX) Company Profile
名前
Travere Therapeutics Inc
セクター
電話
888-969-7879
住所
3611 VALLEY CENTRE DR, SAN DIEGO
Compare TVTX vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
TVTX
Travere Therapeutics Inc
|
57.85 | 5.35B | 536.20M | -45.64M | -28.94M | -0.5348 |
VRTX
Vertex Pharmaceuticals Inc
|
522.25 | 134.41B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
676.23 | 68.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.93 | 57.01B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
321.50 | 41.79B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
190.46 | 40.39B | 742.00K | -1.37B | -1.07B | -7.0731 |
Travere Therapeutics Inc Stock (TVTX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-04-14 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2025-10-31 | 繰り返されました | Citigroup | Buy |
| 2025-06-11 | 繰り返されました | Citigroup | Buy |
| 2025-06-11 | 再開されました | H.C. Wainwright | Buy |
| 2025-01-10 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-10-21 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2024-10-16 | 開始されました | Scotiabank | Sector Outperform |
| 2024-09-09 | アップグレード | Guggenheim | Neutral → Buy |
| 2024-03-27 | ダウングレード | Guggenheim | Buy → Neutral |
| 2023-12-05 | アップグレード | Citigroup | Neutral → Buy |
| 2023-11-20 | 開始されました | Citigroup | Neutral |
| 2023-09-22 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2023-09-21 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2023-09-06 | 再開されました | Evercore ISI | Outperform |
| 2023-07-21 | 開始されました | JP Morgan | Overweight |
| 2023-06-07 | 再開されました | Piper Sandler | Neutral |
| 2023-05-22 | 開始されました | TD Cowen | Outperform |
| 2023-05-05 | アップグレード | Bryan Garnier | Sell → Neutral |
| 2023-03-01 | 開始されました | Guggenheim | Buy |
| 2023-02-21 | アップグレード | Wedbush | Neutral → Outperform |
| 2022-12-14 | 開始されました | Stifel | Hold |
| 2022-12-05 | 開始されました | Wells Fargo | Overweight |
| 2022-09-21 | 開始されました | Bryan Garnier | Sell |
| 2022-07-14 | 再開されました | Canaccord Genuity | Buy |
| 2022-03-31 | 開始されました | Piper Sandler | Overweight |
| 2022-02-28 | 開始されました | H.C. Wainwright | Buy |
| 2021-05-26 | ダウングレード | Wedbush | Outperform → Neutral |
すべてを表示
Travere Therapeutics Inc (TVTX) 最新ニュース
Will Travere’s Removal From Key Russell Value Indices Change Travere Therapeutics' (TVTX) Narrative? - simplywall.st
Everest Medicines Announces Close of Exclusive Licensing Agreement with Travere Therapeutics for Civorebrutinib - The Manila Times
Travere Therapeutics Wins Much-Awaited Approval For Drug In Rare Kidney Disease - Stocktwits
Travere Therapeutics: Filspari Is Becoming A Rare Kidney Disease Platform (NASDAQ:TVTX) - Seeking Alpha
TVTX, LGND Stocks In Spotlight Ahead Of Monday’s FDA Call On Kidney Drug Filspari - Stocktwits
Travere Therapeutics Receives Notice of Allowance from the U.S. P - The National Law Review
Travere Therapeutics, Inc.(NasdaqGM: TVTX) dropped from Russell 2000 Value Benchmark - marketscreener.com
Understanding Momentum Shifts in (TVTX) - Stock Traders Daily
Travere Therapeutics, Inc.(NasdaqGM:TVTX) dropped from Russell Small Cap Comp Value Benchmark - marketscreener.com
TVTX Stock On Track To Hit Near 20-Year Highs After Filspari Becomes The Only Approved FSGS Treatment - Stocktwits
Enterprise value to revenue forward of Travere Therapeutics, Inc. – NASDAQ:TVTX - TradingView
Price to earnings forward of Travere Therapeutics, Inc. – NASDAQ:TVTX - TradingView
Travere Therapeutics, Inc.(NasdaqGM: TVTX) dropped from Russell 3000 Value Benchmark - marketscreener.com
Enterprise value to EBITDA forward of Travere Therapeutics, Inc. – NASDAQ:TVTX - TradingView
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation int - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Is Investigating Travere Thera - The National Law Review
Price to sales forward of Travere Therapeutics, Inc. – NASDAQ:TVTX - TradingView
Travere Therapeutics, Inc. Actuals & Estimates (NASDAQ:TVTX) - TradingView
TVTX Maintained by Guggenheim -- Price Target Raised to $65 - GuruFocus
TVTX Forecast — Price Target — Prediction for 2027 - TradingView
Travere Therapeutics stock hits 52-week high at 56.9 USD By Investing.com - Investing.com Australia
Travere Therapeutics stock hits 52-week high at 56.9 USD - Investing.com
Travere Therapeutics Inc (TVTX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Travere Therapeutics Inc (TVTX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Form 4 Travere Therapeutics Inc For: 22 June By Investing.com - Investing.com South Africa
Travere Therapeutics (NASDAQ: TVTX) CMO gifts 468 shares in Form 4 - Stock Titan
TVTX Maintains by Wedbush -- Price Target Raised to $61.00 - GuruFocus
Travere Therapeutics Shows Favorable Setup With Filspari as Growth Asset, Wedbush Says - marketscreener.com
Travere and Everest Medicines Strike $1.1 Billion Rare Kidney Disease Deal - The Healthcare Technology Report.
A Quick Look at Today's Ratings for Travere Therapeutic(TVTX.US), With a Forecast Between $49 to $67 - Moomoo
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
TVTX Maintained by Evercore ISI Group -- Price Target Raised to $60 - GuruFocus
Travere Therapeutics Inc (TVTX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Travere Therapeutics Inc (TVTX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Travere Therapeutics Inc (TVTX) Institutional Confidence - TradingKey
Travere Therapeutics stock hits 52-week high at 54.49 USD By Investing.com - Investing.com Nigeria
Travere Therapeutics Inc (TVTX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Travere Therapeutics Inc (TVTX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Avoiding Lag: Real-Time Signals in (TVTX) Movement - Stock Traders Daily
Travere Therapeutics Inc (TVTX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Travere Therapeutics Announces R&D Leadership Transition Plan - The Globe and Mail
Travere Therapeutics stock hits 52-week high at 54.49 USD - Investing.com
Travere Therapeutics announces leadership changes in R&D By Investing.com - Investing.com South Africa
Travere Therapeutics, Inc. (TVTX) latest stock news and headlines - Yahoo Finance Singapore
Travere Therapeutics (TVTX) Announces Leadership Change in Resea - GuruFocus
Travere Therapeutics Inc (TVTX) 財務データ
収益
当期純利益
現金流量
EPS
Travere Therapeutics Inc (TVTX) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Coughlin Timothy | Director |
Jun 12 '26 |
Sale |
50.07 |
10,000 |
500,747 |
56,250 |
| Baynes Roy D. | Director |
Jun 12 '26 |
Option Exercise |
21.38 |
4,500 |
96,210 |
46,000 |
| Baynes Roy D. | Director |
Jun 12 '26 |
Sale |
50.00 |
4,500 |
225,000 |
41,500 |
1.18%
2.48%
大文字化:
|
ボリューム (24 時間):